Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

NCT02727881 is registered in ClinicalTrials.gov with Ohr Pharmaceutical Inc. as lead sponsor.

NCT NCT02727881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02727881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Lead sponsor
Ohr Pharmaceutical Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
April 12, 2016
Completion date
December 31, 2017
Enrollment
230 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration